Lung Cancer Program

Question 1

Describe ARCTIC

Answer 1

Phase III, randomized, open label, global, multicentre
EGFR/ALK WT NSCLC patients Stage IIIB/IV who have failed at least 2 prior regimens (1 Pt-containing)
2 cohorts, one with 2 subcohorts, one with 4
A: PD-L1+ with SoC or durva mono
B: PD-L1- with durva mono, treme mono, combo, or SoC

Question 2

Describe PACIFIC

Answer 2

Phase III, randomized, double-blind, placebo controlled, multicentre
Locally advanced unresectable NSCLC (squamous or non) Stage III with absence of progression following at least two cycles of Pt-based therapy concomitant with radiation therapy
Durva mono vs placebo

Question 3

Describe MYSTIC

Answer 3

Phase III randomized, open-label, global study
First line advanced or metastatic NSCLC, EGFR/ALK WT
durva mono vs durva combo vs SoC

Question 4

Describe Adjuvant NCIC

Answer 4

Phase III, randomized
Stage Ib-IIIa resected NSCLC
Durva mono vs placebo

Question 5

Describe ATLANTIC

Answer 5

Phase II noncomparative, open label multicentre
Stage IIIB/IV NSCLC who have failed at least 2 prior regimen (one Pt-containing)
Durva monotherapy
3 cohorts: 1. EGFR/ALK mut+, PD-L1+ (>25% tumour cells)
2. EGFR/ALK WT, PD-L1+ (>25% tumour cells)
3. EGFR/ALK WT, PD-L1+ (>90% tumour cells)